GlassScriptPhysician profile
Jeffrey A Shehane
NPI 1295022721
$2,622.18
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $503.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,313.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $270.93 | 2019-2020 | |
| Insmed, INC. | $210.13 | 2019-2020 | |
| United Therapeutics Corporation | $166.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.66 | 2019 | |
| Electromed, INC. | $159.99 | 2019 | |
| Mylan Specialty L.P. | $83.59 | 2019 | |
| Grifols USA, LLC | $55.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.84 | 2019-2020 | |
| Advanced Respiratory, INC | $28.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.27 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.10 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.02 | 2019 | |
| Circassia INC. | $17.75 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.78 | 2020 | |
| Genentech USA, INC. | $11.83 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shehane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.